Journal Reviews

Systemic rituximab immunotherapy in the management of primary ocular adnexal lymphoma single institutional experience

1 October 2015 | | Oculoplastics, Orbit | Extranodal marginal zone lymphoma, Rituximab, immunotherapy, lymphoma, ocular adnexa

Ocular adnexal lymphomas constitute 2% of all non-Hodgkin’s disease and 5-15% of all extranodal lymphomas and are usually localised, low-grade and of B-cell origin. This opens them up to potential treatment with a systemic monoclonal antibody-based drug (rituximab) directed at...